A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease

Published:2018-05-22 Issue:1 Volume:8 Page:49-59
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Spiegelstein Ofer¹,Mimrod Dorit²,Rabinovich Laura³,Eyal Eli⁴,Sprenger Craig⁵,Elgart Anna¹,Samara Emil⁶,Morganroth Joel⁷

Affiliation:

1. Clinical Pharmacology and Pharmacometrics; Teva Pharmaceutical Industries Ltd; Netanya Israel

2. Project Leadership; Teva Pharmaceutical Industries Ltd; Netanya Israel

3. Clinical Pharmacology and Pharmacometrics; Teva Pharmaceutical Industries Ltd; Frazer PA USA

4. Global Biostatistics Unit; TEVA Pharmaceutical Industries Ltd; Netanya Israel

5. Novum; Fargo ND USA

6. PharmaPolaris International; Davis CA USA

7. eResearch Technology, Inc; Philadelphia PA USA

Funder

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.442/fullpdf

Reference30 articles.

1. Insight into the mechanism of laquinimod action;Brück;J Neurol Sci,2011

2. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod;Mishra;Am J Pathol,2012

3. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity;Schulze-Topphoff;PLoS One,2012

4. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis;Jolivel;Brain,2013

5. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis;Wegner;J Neuroimmunol,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator;Clinical Pharmacology in Drug Development;2020-04

2. The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials;European Journal of Clinical Pharmacology;2020-02-04

3. How to Prescribe Drugs With an Identified Proarrhythmic Liability;The Journal of Clinical Pharmacology;2019-11-19

4. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women;European Journal of Clinical Pharmacology;2018-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3